Company Filing History:
2 out of 289 
1 out of 8 
1 out of 1 
Years Active: 2019-2021
Title: Susanna Carolina Berger: Innovator in Cellular Immunotherapy
Introduction
Susanna Carolina Berger is a prominent inventor based in Seattle, WA (US). She has made significant contributions to the field of cellular immunotherapy, holding a total of 3 patents. Her work focuses on enhancing the efficacy of immunotherapy treatments, particularly through the use of modified T cells.
Latest Patents
One of her latest patents is titled "Adoptive transfer of CD8+ T cell clones derived from central memory cells." This invention provides a method for carrying out adoptive immunotherapy in primate subjects by administering a cytotoxic T lymphocytes (CTL) preparation. The method involves using an in vitro expanded primate CTL population that is enriched for central memory T lymphocytes and depleted of effector memory T lymphocytes. Additionally, the method may include the concurrent administration of Interleukin-15 to enhance the proliferation of central memory T cells in the subject.
Another significant patent is "Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy." This disclosure presents compositions and methods aimed at augmenting the effectiveness of adoptive cellular immunotherapy. It involves using modified T cells that express an antigen binding protein alongside modified cells that express the antigen specifically bound by the T cells' antigen binding protein.
Career Highlights
Susanna has worked with notable institutions such as the Fred Hutchinson Cancer Center and the Fred Hutchinson Cancer Research Center. Her research has been pivotal in advancing the understanding and application of immunotherapy techniques.
Collaborations
Throughout her career, Susanna has collaborated with esteemed colleagues, including Stanley R. Riddell and Michael C. Jensen. These partnerships have contributed to her innovative approaches in the field of immunotherapy.
Conclusion
Susanna Carolina Berger is a trailblazer in the realm of cellular immunotherapy, with her patents reflecting her commitment to improving treatment methodologies. Her work continues to influence the landscape of immunotherapy, showcasing the potential of innovative approaches in medicine.